Dupilumab Treatment Efficacy and Impact on Clinical Scores, Serum Biomarkers, and Itch in Adult Patients with Atopic Dermatitis: A Retrospective Analysis

PURPOSE: Dupilumab, a fully human monoclonal antibody that inhibits the signaling pathways of interleukin (IL)-4 and IL-13, has demonstrated remarkable efficacy in the treatment of atopic dermatitis (AD). Dupilumab has been reported to attenuate itch and reduce several serum markers, including blood...

Descripción completa

Detalles Bibliográficos
Autores principales: Rossi, Mariateresa, Bettolini, Luca, Artelli, Grazia Linda, Fraghì, Alessandro, Tomasi, Cesare, Calzavara-Pinton, Piergiacomo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10642571/
https://www.ncbi.nlm.nih.gov/pubmed/37965272
http://dx.doi.org/10.2147/JAA.S433515

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10642571/
https://www.ncbi.nlm.nih.gov/pubmed/37965272
http://dx.doi.org/10.2147/JAA.S433515

Ejemplares similares